bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 08:45PM GMT
Release Date Price: $8.92 (-6.79%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone, from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov, and I'm the senior large cap biotech analyst here. It's my pleasure to introduce our next company, bluebird bio and CEO, Andrew Obenshain. And please note that following the presentation, we will move right into a Q&A session where you can also send any questions via the conference portal, and I'll do my best to work them into the conversation.

So with that, Andrew, thanks for joining us today. Let me turn things over to you for the latest on bluebird.

Andrew Obenshain
bluebird bio, Inc. - CEO & Director

Thanks, Cory, and thank you very much, JPMorgan, for giving us this opportunity to talk about bluebird bio at this year's conference. So as Cory said, I'm Andrew Obenshain. I am the CEO of bluebird, as of November 4 last year. And I'm excited to present to you all today and tell you about the incredible opportunity that bluebird has to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot